Methyldopa liver damage

Area of Science:

• Hepatology
• Clinical Pharmacology
• Drug-Induced Liver Injury

Background:

• Methyldopa is a medication commonly prescribed for hypertension.
• Drug-induced liver injury (DILI) is a significant concern in pharmacotherapy.

Purpose of the Study:

• To investigate the direct relationship between methyldopa administration and liver damage.
• To characterize the clinical presentation and outcomes of methyldopa-induced hepatotoxicity.

Main Methods:

• Case series describing twenty patients with suspected methyldopa-related liver injury.
• Clinical observation of patient recovery after drug withdrawal and assessment of recurrence upon re-challenge.

Main Results:

• Twenty patients presented with liver damage attributed to methyldopa.
• Sixteen patients developed hepatitic syndromes, with four experiencing recurrent jaundice upon methyldopa re-challenge.
• Two fatalities were linked to methyldopa, including one in a patient with underlying cirrhosis.

Conclusions:

• Methyldopa can be directly associated with significant liver damage, including hepatitic syndromes and jaundice.
• Recurrence of liver injury is possible with re-exposure to methyldopa.
• Clinicians should be vigilant for methyldopa-induced hepatotoxicity, especially in patients with pre-existing liver conditions.